Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.

Original reporting
Published Nov 12, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone — source image
Decision brief

The 30-second read

$PHVSBullishMed
01

Why it matters

The successful Phase 3 readout is a fresh, material development that could trigger a price rally ahead of the anticipated NDA submission.

02

Market read

First disclosure of pivotal trial success; likely to move PHVS and related rare‑disease biotech stocks.

03

What to watch

The company’s cash runway and upcoming NDA filing timelines may limit upside if financing is needed.

Relevance 8/10Novelty 8/10Timing: today

Background

Pharvaris (PHVS) provided a brief Q3 2026 update focusing on late‑stage development milestones for its HAE candidates.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

Pharvaris announced a successful pivotal Phase 3 readout for deucrictibant XR and disclosed NDA timelines, a new clinical‑trial milestone.

Expected impact

upward pressure as market anticipates regulatory approval and commercial launch

Evidence & confidence

Phase 3 success is a material catalyst for biotech stocks; no prior public disclosure of this readout.

Market effects

Strengthens outlook for the hereditary angioedema therapeutic segment.

Potentially benefits European biotech investors tracking rare‑disease pipelines.

Adds to the pipeline momentum in the global rare‑disease biotech space.

Counterpoint

If regulatory hurdles delay, the stock could face disappointment despite trial success.

Key entities

  • Pharvaris

    Biotech firm developing deucrictibant for hereditary angioedema.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.